1/21/25 - RIGL: new BUY mechanical trading signal.1/21/25 - RIGL: new BUY signal chosen by a rules based, mechanical trading system.
RIGL - BUY
Stop Loss @ 16.25
Entry BUY @ 21.81
Target Profit @ 27.80
Analysis:
Higher timeframe: Prices have stayed above the lower channel line of the ATR (Average True Range) Keltner Channel and reversed.
Highe
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.898 CHF
15.88 M CHF
162.82 M CHF
17.38 M
About Rigel Pharmaceuticals, Inc.
Sector
Industry
CEO
Raul R. Rodriguez
Website
Headquarters
South San Francisco
Founded
1996
FIGI
BBG00LVG9RT3
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Watchlist 2023-03-07 $OPK $RIGL $WE SPY - flat this morning as we await the second testimonial day for FED chair Powell. There has been lots of opportunity in small caps the past week so shifting focus there, also to avoid the chop that we see in large cap on Fed days.
OPK - Opko health sign deal for experimental Epstein-Barr virus
RIGL - trending upwardsLooking to take an entry at 1.05 if volume and technicals look promising for Monday. A break below $1 would turn this into a bearish play for me.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders (or potential shareholders) will be happy to see that the President, Raul Rodriguez, recently boug
Rigel Pharmaceuticals doing a thing. RIGLNot quite going to Rigel, but showing more and more promise of higher highs in the not so distant future. Looking quite optimal fractally, actually.
Fibonacci goals are in green, reversal or invalidation is in red. This post is not financial advice, make your own financial advice or pay a certified
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange RIGEL PHARMACEUTIC stocks are traded under the ticker RIGL.
RIGL stock has risen by 1.04% compared to the previous week, the month change is a 1.04% rise, over the last year RIGEL PHARMACEUTIC has showed a 1.04% increase.
We've gathered analysts' opinions on RIGEL PHARMACEUTIC future price: according to them, RIGL price has a max estimate of 50.24 CHF and a min estimate of 17.63 CHF. Watch RIGL chart and read a more detailed RIGEL PHARMACEUTIC stock forecast: see what analysts think of RIGEL PHARMACEUTIC and suggest that you do with its stocks.
RIGL reached its all-time high on Mar 17, 2025 with the price of 17.874 CHF, and its all-time low was 17.630 CHF and was reached on Mar 17, 2025. View more price dynamics on RIGL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RIGL stock is 1.38% volatile and has beta coefficient of 1.91. Track RIGEL PHARMACEUTIC stock price on the chart and check out the list of the most volatile stocks — is RIGEL PHARMACEUTIC there?
Today RIGEL PHARMACEUTIC has the market capitalization of 243.65 M, it has increased by 3.30% over the last week.
Yes, you can track RIGEL PHARMACEUTIC financials in yearly and quarterly reports right on TradingView.
RIGEL PHARMACEUTIC is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
RIGL earnings for the last quarter are 0.73 CHF per share, whereas the estimation was 0.41 CHF resulting in a 77.48% surprise. The estimated earnings for the next quarter are 0.079 CHF per share. See more details about RIGEL PHARMACEUTIC earnings.
RIGEL PHARMACEUTIC revenue for the last quarter amounts to 52.31 M CHF, despite the estimated figure of 45.50 M CHF. In the next quarter, revenue is expected to reach 38.84 M CHF.
RIGL net income for the last quarter is 13.02 M CHF, while the quarter before that showed 10.53 M CHF of net income which accounts for 23.74% change. Track more RIGEL PHARMACEUTIC financial stats to get the full picture.
No, RIGL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 164 employees. See our rating of the largest employees — is RIGEL PHARMACEUTIC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. RIGEL PHARMACEUTIC EBITDA is 23.99 M CHF, and current EBITDA margin is 14.74%. See more stats in RIGEL PHARMACEUTIC financial statements.
Like other stocks, RIGL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade RIGEL PHARMACEUTIC stock right from TradingView charts — choose your broker and connect to your account.